Related Experiment Video
Updated: Jan 29, 2026
Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
Published on: December 31, 2007
Therapeutic potential of melatonin agonists
Daniel P Cardinali1, Seithikurippu R Pandi-Perumal2, Venkataramanujan Srinivasan3
1a Departamento de Fisiología, Facultad de Medicina, UBA Paraguay 2155, 1121 Buenos Aires, Argentina. dcardinali@fmed.uba.ar.
Melatonin and its agonists, like ramelteon and agomelatine, effectively treat sleep disorders by targeting MT1/MT2 receptors. These treatments improve sleep efficiency and regulate circadian rhythms, offering solutions for insomnia and depression-related sleep issues.
Area of Science:
- Neuroscience
- Pharmacology
- Sleep Medicine
Background:
- Melatonin, a pineal gland hormone, regulates sleep and circadian rhythms via MT1/MT2 receptors in the suprachiasmatic nucleus.
- Existing melatonin therapies face challenges due to variable bioavailability and short half-life.
- Newer melatonergic agonists are being developed to overcome these limitations.
Purpose of the Study:
- To review the therapeutic applications of melatonin and novel melatonergic agonists.
- To highlight the role of MT1/MT2 receptors in sleep regulation.
- To discuss the efficacy of ramelteon, agomelatine, and slow-release melatonin.
Main Methods:
- Review of scientific literature on melatonin, ramelteon, agomelatine, and Circadin.
- Analysis of clinical studies on sleep disorders and major depressive disorder.
- Focus on melatonergic agonism and its effects on sleep and circadian rhythms.
Main Results:
- Ramelteon demonstrates clinical efficacy in improving sleep time and efficiency for insomniacs.
- Agomelatine, a dual MT1/MT2 agonist and 5-HT2C antagonist, effectively treats depression and associated sleep disorders.
- Slow-release melatonin (Circadin) is effective for sleep disorders in the elderly.
Conclusions:
- Melatonergic agonists offer promising therapeutic options for various sleep disorders.
- Targeting MT1/MT2 receptors is a validated strategy for sleep and circadian rhythm management.
- Further research into long-acting agonists may improve treatment consistency and patient outcomes.
More Related Videos
12:02Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
04:50Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
Published on: August 4, 2023
Related Concept Videos
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:18Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:13Therapeutic Index
01:25Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...